How Tesamorelin Affects Fasting Glucose

Tesamorelin preserves glucose homeostasis through a pulsatile, physiological GH release pattern:

1. Pulsatile vs continuous GH: Tesamorelin triggers endogenous GH pulses through GHRH receptor activation, preserving the normal feedback loop (IGF-1 to somatostatin). This contrasts with exogenous HGH or CJC-1295 DAC, which create a continuous supraphysiologic GH bleed that drives insulin resistance.
2. Inter-pulse insulin sensitivity recovery: Between GH pulses, insulin sensitivity returns to baseline. Continuous GH exposure does not allow this recovery, which is why exogenous HGH at bodybuilding doses (2-4 IU/day) consistently raises fasting glucose 10-20 mg/dL within weeks.
3. Visceral fat reduction offsets metabolic cost: Tesamorelin's primary effect is visceral fat mobilisation. As VAT decreases, portal free fatty acid flux to the liver drops, hepatic insulin sensitivity improves, and the small acute glucose effect of GH pulses is offset by the chronic metabolic improvement.
4. Direct evidence in healthy men: Stanley et al. (2011, PMID 20943777) used a hyperinsulinaemic-euglycaemic clamp in healthy men on 2 mg/day for 2 weeks. Insulin-stimulated glucose uptake was unchanged (p=0.61), confirming that pulsatile GHRH stimulation does not impair peripheral insulin sensitivity.

Standard dose (1.4-2 mg/day, subcutaneous):

• Fasting glucose: no clinically meaningful change in the pooled Phase 3 dataset (n=806, 52 weeks)
• Responders (≥8% VAT reduction at 26 weeks): fasting glucose change +1 mg/dL at week 26 (Stanley CID 2012, PMID 22495074)
• Non-responders: fasting glucose drift +5 to +8 mg/dL at week 26 (the gap is the key signal)
• Transient effect: a small fasting glucose bump may occur at week 2 (Stanley JAMA 2014) but resolves by month 3

Comparison to other GH-axis compounds:

• Tesamorelin: neutral (clamp p=0.61)
• MK-677: fasting glucose +26% at 4 weeks (Chapman 1996, PMID 8954023)
• Exogenous HGH at 2-4 IU/day: +10-20 mg/dL within 4-8 weeks, dose-dependent

Timeline: Glucose neutrality is established by 4-12 weeks in responders. Non-responders show drift detectable by week 12-26.

Baseline: Fasting glucose, HbA1c, fasting insulin (calculate HOMA-IR), before starting.

During use:

• Fasting glucose at week 4 (catch early drift)
• Fasting glucose, HbA1c, fasting insulin at week 12 (the decision point)
• Repeat at week 26 (the efficacy and continuation gate)
• Every 12 weeks thereafter if continuing

Decision rules:

• Fasting glucose drift <5 mg/dL: continue
• Fasting glucose drift 5-10 mg/dL: tighten diet, recheck at week 16
• Fasting glucose >110 mg/dL on two readings: reduce to 1 mg/day or pause
• HbA1c crosses 6.5%: hard stop (FDA label line)

Important context: The Phase 3 trials showed a small but real signal: 5% of patients developed HbA1c >=6.5% on tesamorelin vs 1% on placebo (hazard ratio 3.3). This is why baseline + week 12 + week 26 monitoring is non-negotiable.

Preserving glucose neutrality:

• Inject at bedtime on an empty stomach. Elevated insulin or glucose at injection time blunts the somatotrope response and may shift the metabolic balance unfavourably.
• Do not stack with exogenous HGH or MK-677. Layering pulsatile GHRH stimulation on top of continuous GH exposure removes tesamorelin's metabolic advantage.
• Pair with a GLP-1 (semaglutide, tirzepatide) if baseline fasting glucose is already creeping. The combination targets visceral fat from two angles without the insulin resistance cost.

If glucose drift appears:

• First, verify the draw was truly fasted (12-14 hours, no caffeine).
• Second, check that you are a VAT responder. If you have measurable VAT reduction at week 26, the small glucose drift is likely tolerable. If you are not responding on VAT, discontinue.
• Third, consider 1 mg/day instead of 1.4-2 mg/day. The Clemmons 2017 T2D trial (PMID 28617838) showed 1 mg produced real IGF-1 elevation with lower side effect burden.

Hard stop conditions:

• HbA1c >=6.5%
• Persistent fasting glucose >126 mg/dL
• IGF-1 >3 SDS above age-adjusted normal (FDA label)